Tolero Pharmaceuticals, Inc.

Sumitomo Pharma Oncology, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Jason Marc Foulks

Koc-Kan Ho

Yong Xu

Xiaohui Liu

Jihua Liu

Kenneth Mark Parnell

Michael David Saunders

Kevin Bret Wright

Scott Albert Pearce

Steven Brian Kanner

David Lee Vollmer

David J Bearss

Steven L Warner

Adam Siddiqui-Jain

Paul Flynn

Clifford J Whatcott

Yuka Arikawa

Hiroki Umehara

Yuji Fujiwara

Akihito Nonoyama

Akihito Kiguchiya

Nozomi Tomimatsu

Ken Fujimura

Stephen Patrick Anthony

Micheal David Saunders

A compound of Structure (I): or a pharmaceutically acceptable salt thereof, alone or in combination with a second therapeutic agent, as well as methods of treating a PKM2-mediated disease or disorder using the same are provided herein.

Compositions comprising PKM2 modulators and methods of treatment using the same

Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.

AXL kinase inhibitors and use of the same

Methods for treating a disease in a subject in need thereof by administering an ACVR1 inhibitor having the following formula (I) are disclosed: including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, and Rare as defined herein. Subjects that may benefit from treatment may have mutations in their ACVR1 gene. Various diseases may be treated using the described methods, including cancers (e.g., diffuse intrinsic pontine glioma (DIPG)) and genetic disorders (e.g., fibrodysplasia ossificans progressiva (FOP)).

Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

PKM2 modulators and methods for their use

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Growing community of inventors

Sandy, UT, United States of America

Jason Marc Foulks